IXICO announces its real world study of Digital Biomarkers in people with dementia

IXICO today announces that John Hall, IXICO’s SVP Commercial Operations, and Ken Tubman, IXICO’s VP Health Technology, are delivering a presentation on Digital Biomarkers in Alzheimer’s Disease at the Coalition Against Major Diseases (CAMD) Critical Path Institute’s Digital Biomarkers Conference in Bethesda, Maryland, USA. The conference, titled “Use of Biosensors in Clinical Trials: Barriers & Solutions to the Current Landscape”, will examine the current landscape of the use of Digital Biomarkers in clinical trials of neurodegenerative diseases, the challenges faced and the need for new solutions.

IXICO’s presentation describes how wearable devices and mobile phone apps are being used in Cygnus, a real world study of patients with symptoms of cognitive impairment and possible dementia. Cygnus has received favourable opinion from the Research Ethics Committee and recruitment is expected to commence shortly.

PRESS RELEASE
By | 2017-10-10T15:49:57+00:00 31 March 2016|Events|